The cardiovascular drugs market consists of sales of cardiovascular drugs and related services by entities (organizations, sole traders and partnerships) that produce cardiovascular drugs to treat cardiovascular diseases. This industry includes establishments that produce anti-hypertensive drugs to prevent heart failure by controlling blood pressure and hypolipidemic drugs that reduce lipid and lipoprotein levels in the blood. It also consists of establishments which produce antithrombotic drugs to treat arterial and venous thrombosis.
The cardiovascular drugs market expected to reach a value of nearly $86.67 billion by 2022, significantly growing at a CAGR of 1.2% during the forecast period. The growth in the Cardiovascular drugs market is due to increase in aging population, increase in the prevalence of cardiovascular diseases and availability of more generic drugs that reduce the cost of treatment.
View complete Report: https://www.thebusinessresearchcompany.com/report/cardiovascular-drugs-global-market-report
NOACs are gaining wider acceptance and are replacing traditionally used anti-coagulants such as Warfarin and Heparin. Anti-coagulants have long been used in prevention of thrombus formation in patients suffering with cardiovascular diseases. Use of NOACs makes it easier for patients to continue therapy post discharge as opposed to injections of Heparin and Warfarin which need medical assistance for administration. Some of the NOACs include Pradaxa (dabigatran etexilate) from Boehringer Ingelheim, Xarelto (rivaroxaban) from Janssen, and Eliquis (apixaban) from Bristol-Myers Squibb.
The global cardiovascular drugs is segmented into North America, South America, Asia-Pacific, Eastern Europe, Western Europe, Middle East and Africa. Among these regions, Asia Pacific was the largest region in the global cardiovascular drugs market.
Request a Sample Report At: https://www.thebusinessresearchcompany.com/sample.aspx?id=2134&type=smp
Table Of Content
1. Executive Summary
2. Report Structure
3. Cardiovascular Drugs Market Characteristics
4. Cardiovascular Drugs Market Product Analysis
5. Cardiovascular Drugs Market Supply Chain
6. Cardiovascular Drugs Market Customer Information
7. Cardiovascular Drugs Market Trends And Strategies
8. Cardiovascular Drugs Market Size And Growth
9. Cardiovascular Drugs Market Regional Analysis
10. Cardiovascular Drugs Market Segmentation
11. Cardiovascular Drugs Market Metrics
12. Asia-Pacific Cardiovascular Drugs Market
13. Western Europe Cardiovascular Drugs Market
14. Eastern Europe Cardiovascular Drugs Market
15. North America Cardiovascular Drugs Market
16. South America Cardiovascular Drugs Market
17. Middle East Cardiovascular Drugs Market
18. Africa Cardiovascular Drugs Market
19. Cardiovascular Drugs Market Competitive Landscape
20. Key Mergers And Acquisitions In The Cardiovascular Drugs Market
21. Market Background: Pharmaceutical Drugs Market
22. Recommendations
23. Appendix
24. Copyright And Disclaimer
Avail Discount On This Report: https://www.thebusinessresearchcompany.com/sample.aspx?id=2134&type=discount
About Us:
The Business Research Company is a Business Intelligence Company which excels in company, market and consumer research. It has offices in the UK, the US and India and a network of trained researchers in 15 countries globally.
Contact Information:
The Business Research Company
Europe: +44 207 1930 708
Asia: +91 8897263534
Americas: +1 315 623 0293
Email: info@tbrc.info
Follow us on LinkedIn: https://in.linkedin.com/company/the-business-research-company
